BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30747220)

  • 21. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
    Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
    Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
    Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
    BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA.
    Pan Y; Qin T; Yin S; Zhang X; Gao X; Mu L
    Biomed Pharmacother; 2017 Mar; 87():669-677. PubMed ID: 28088733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.
    Yang SZ; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2015 Jul; 21(27):8418-24. PubMed ID: 26217094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide.
    Cui L; Gao B; Cao Z; Chen X; Zhang S; Zhang W
    Mol Med Rep; 2016 Mar; 13(3):2032-8. PubMed ID: 26781180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F; Cai D
    Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.
    Wang K; Liang Q; Wei L; Zhang W; Zhu P
    Tumour Biol; 2016 Mar; 37(3):3823-30. PubMed ID: 26474589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
    Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
    Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA NRON is downregulated in HCC and suppresses tumour cell proliferation and metastasis.
    Yao Z; Xiong Z; Li R; Liang H; Jia C; Deng M
    Biomed Pharmacother; 2018 Aug; 104():102-109. PubMed ID: 29772429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-7 downregulates the oncogene VDAC1 to influence hepatocellular carcinoma proliferation and metastasis.
    Wang F; Qiang Y; Zhu L; Jiang Y; Wang Y; Shao X; Yin L; Chen J; Chen Z
    Tumour Biol; 2016 Aug; 37(8):10235-46. PubMed ID: 26831666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-493 suppresses cell proliferation and invasion by targeting ZFX in human hepatocellular carcinoma.
    Ding W; Tan H; Li X; Zhang Y; Fang F; Tian Y; Li J; Pan X
    Cancer Biomark; 2018; 22(3):427-434. PubMed ID: 29758928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel role of semaphorin 3A in the growth and progression of hepatocellular carcinoma.
    Li X; Chen Q; Yin D; Shi S; Yu L; Zhou S; Chen E; Zhou Z; Shi Y; Fan J; Zhou J; Dai Z
    Oncol Rep; 2017 Jun; 37(6):3313-3320. PubMed ID: 28498470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
    Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
    Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
    Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
    Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity.
    Wu XS; Bao TH; Ke Y; Sun DY; Shi ZT; Tang HR; Wang L
    Tumour Biol; 2016 Nov; 37(11):14711-14719. PubMed ID: 27623945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
    Yu Y; Chen X; Zhang W; Liu J
    Biomed Res Int; 2021; 2021():4051192. PubMed ID: 34957303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
    Jin Y; Wang J; Han J; Luo D; Sun Z
    Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.
    Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D
    Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.